Northern Trust’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Northern Trust’s Portfolio CYTH Stock Details CYTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-21,736	Closed	-$12.8K	–	4515
2024 Q4	$12.8K	Buy	21,736 +14	+0.1%	+$10	﹤0.01%	4407
2024 Q3	$17.1K	Hold	21,722	–	–	﹤0.01%	4350
2024 Q2	$27.6K	Sell	21,722 -19	-0.1%	-$25	﹤0.01%	4297
2024 Q1	$30.2K	Buy	21,741 +4,288	+25%	+$7.09K	﹤0.01%	4296
2023 Q4	$27.8K	Buy	17,453 +860	+5%	+$1.1K	﹤0.01%	4330
2023 Q3	$23.6K	Hold	16,593	–	–	﹤0.01%	4306
2023 Q2	$26.4K	Buy	+16,593	New	+$21.2K	﹤0.01%	4352

Northern Trust's CYTH Position: Q1 2025 in Review

Northern Trust sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2025, closing a stake of 21,736 shares — an estimated $12.8K sold.

Northern Trust first reported a position in CYTH in Q2 2023 and held it in 7 quarters. The position peaked at $30.2K in Q1 2024. 0 funds tracked by Wall St. Rank hold CYTH as of Q1 2025.

Northern Trust reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Northern Trust sold 21,736 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $12.8K.
Northern Trust first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q2 2023 and held it in 7 quarters.
Northern Trust's Cyclo Therapeutics, Inc. Common Stock position peaked at $30.2K in Q1 2024.
0 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Northern Trust's 13F filing for Q1 2025, filed 13 May 2025.